InvestSMART

Artrya Limited (ASX:AYA)

ALERT: Price-sensitive ASX Announcement for AYA
Current share price for AYA : $5.510 1.39 (33.74%)+
Announcement
Release
30 Apr 2026 9:15AM
Price at Release
$4.120
Full Release
download
Summary
Artrya Limited reported significant progress in the commercial roll-out of its Salix® AI-powered platform for coronary artery disease management during the quarter ended 31 March 2026. Key activities included full integration of the Salix® platform in Tanner Health hospitals and advancements towards go-live with Northeast Georgia Health System and Cone Health. The Salix® Coronary Flow module is nearing FDA submission, and the SAPPHIRE Study is underway with contracting and ethics approvals. Financially, Artrya reported a net cash inflow of $0.06M, with a strong cash position of $76.6M. The company was also included in the S&P/ASX All Ordinaries Index, increasing its visibility among investors.
Key Points
  • Salix® platform fully integrated across Tanner Health hospitals.
  • Northeast Georgia Health System and Cone Health preparing for Salix® integration.
  • Salix® Coronary Flow module nearing FDA submission.
  • SAPPHIRE Study contracting and ethics submissions underway.
  • Net cash inflow of $0.06M for the quarter.
  • Cash position at $76.6M.
  • Included in the S&P/ASX All Ordinaries Index.
  • Strengthened U.S. leadership and board appointments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.